Clinical Trials Logo

Filter by:
NCT ID: NCT00255606 Completed - Prostate Cancer Clinical Trials

Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer

Start date: August 2005
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which schedule of docetaxel and prednisone is more effective in treating prostate cancer. PURPOSE: This randomized phase III trial is studying two different schedules of docetaxel and prednisone to compare how well they work in treating patients with metastatic prostate cancer.

NCT ID: NCT00255593 Completed - Clinical trials for Renal Transplantation

Safety and Efficacy Study of Rituximab in Renal Transplantation

Start date: November 2005
Phase: Phase 1
Study type: Interventional

Current strategies for the medical management of transplant patients are largely focused on the prevention and treatment of T-lymphocyte mediated processes. However there is an increasing evidence to suggest that B-lymphocytes have a role in the otherwise classic T-cell mediated rejection of transplants by there ability to act as antigen presenting cells and T-cell activators. Thus there is a significant medical need for effective therapies targeting B cells of transplant patients.One such potential therapy would be to use rituximab, a monoclonal antibody against B-cells in all renal transplant patients. In the present study the efficacy and safety of prophylactic rituximab is studied.

NCT ID: NCT00255515 Completed - Schizophrenia Clinical Trials

Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia

SCORE
Start date: September 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare efficacy of quetiapine fumarate combined with Cognitive Remediation Therapy (CRT) to conventional treatment by evaluating change in social outcome in patients with schizophrenia.

NCT ID: NCT00255463 Completed - Breast Cancer Clinical Trials

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

Start date: January 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the changes in a proliferation biomarker in subjects receiving Anastrozole or Anastrozole/ZD1839 combination.

NCT ID: NCT00255281 Completed - Atrial Fibrillation Clinical Trials

Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation

Start date: September 2005
Phase: Phase 2
Study type: Interventional

The current study is designed to assess the efficacy and safety of iv AZD7009 in conversion from AF

NCT ID: NCT00254891 Terminated - Clinical trials for Carcinoma, Non-Small-Cell Lung

Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer

Start date: November 2005
Phase: Phase 3
Study type: Interventional

To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel/carboplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of paclitaxel

NCT ID: NCT00252837 Terminated - Type 2 Diabetes Clinical Trials

GALLANT 22 Tesaglitazar vs. Placebo

Start date: April 2005
Phase: Phase 3
Study type: Interventional

This is a 24-week randomized, double-blind, parallel-group, multi-center, placebo-controlled study of tesaglitazar (0.5 and 1 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 6-week single-blind placebo run-in period, followed by 24-week treatment period and a 3-week follow-up period. The study design of GALLANT 2 is identical to GALLANT 22; the blinded study data from GALLANT 2 will be transferred to the GALLANT 22 database and will be analyzed together with the data from GALLANT 22 clinical study.

NCT ID: NCT00252005 Completed - Clinical trials for Deep-Vein Thrombosis

Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

Start date: November 2005
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or fondaparinux and vitamin K antagonist in the treatment of subjects with acute symptomatic deep-vein thrombosis.

NCT ID: NCT00251992 Completed - Dyspepsia Clinical Trials

Nexium Dyspepsia/AST

Start date: December 2002
Phase: Phase 3
Study type: Interventional

The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.

NCT ID: NCT00251979 Completed - Clinical trials for Gastrointestinal Hemorrhage

A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer

Start date: October 2005
Phase: Phase 3
Study type: Interventional

This study is being carried out to see if constant 3 days infusion of Nexium is effective in preventing rebleeding after an endoscopic treatment.